Articles related to Urology

Prebiopsy prostate MRI use increased substantially across US hospitals between 2017 and 2026, reflecting broader uptake of guideline-supported imaging, although a substantial proportion of patients still undergo biopsy without MRI evaluation.

Prostate cancer screening continues to rely on individualized risk assessment, PSA monitoring, and shared decision-making, while advances in MRI imaging and biomarker testing may help refine biopsy decisions and reduce unnecessary invasive procedures.

National Cancer Database data suggest that approximately half of prostate cancer focal therapy use from 2010 to 2023 occurred outside current guideline-supported settings, highlighting persistent gaps between clinical practice and available evidence.

Tranexamic acid was associated with lower rates of major bleeding among patients undergoing urologic surgery in a prespecified POISE-3 trial analysis, while thrombotic event rates remained similar between treatment groups.

Radiation oncology practices report substantial revenue declines following 2026 CMS coding changes, with some centers citing reimbursement reductions of 15% to 30%. Stakeholders warn the financial pressures could affect treatment access, particularly in community and rural settings.

Artificial intelligence tools are increasingly being integrated into prostate cancer imaging, pathology, prognostication, and treatment planning. Although several platforms have demonstrated promising accuracy and workflow benefits, broad clinical adoption will require prospective validation, regulatory oversight, and careful implementation.